Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis.

Andersen BJ, Kumar J, Curtis K, Sanuku N, Satofan S, King CL, Fischer PU, Weil GJ.

J Infect Dis. 2018 Jan 4;217(2):280-287. doi: 10.1093/infdis/jix578.

2.

Predicting lymphatic filariasis transmission and elimination dynamics using a multi-model ensemble framework.

Smith ME, Singh BK, Irvine MA, Stolk WA, Subramanian S, Hollingsworth TD, Michael E.

Epidemics. 2017 Mar;18:16-28. doi: 10.1016/j.epidem.2017.02.006.

3.

What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs.

Kastner RJ, Stone CM, Steinmann P, Tanner M, Tediosi F.

PLoS Negl Trop Dis. 2015 Oct 9;9(10):e0004147. doi: 10.1371/journal.pntd.0004147. eCollection 2015.

4.

Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Ramaiah KD, Ottesen EA.

PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319. doi: 10.1371/journal.pntd.0003319. eCollection 2014 Nov.

5.

A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration.

Rao RU, Nagodavithana KC, Samarasekera SD, Wijegunawardana AD, Premakumara WD, Perera SN, Settinayake S, Miller JP, Weil GJ.

PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3281. doi: 10.1371/journal.pntd.0003281. eCollection 2014. Erratum in: PLoS Negl Trop Dis. 2014 Dec;(12):e3428.

6.

Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges.

Tediosi F, Steinmann P, de Savigny D, Tanner M.

PLoS Negl Trop Dis. 2013 Nov 7;7(11):e2446. doi: 10.1371/journal.pntd.0002446. eCollection 2013 Nov. No abstract available.

7.

Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.

Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, Goldman AS.

PLoS Negl Trop Dis. 2013;7(1):e1984. doi: 10.1371/journal.pntd.0001984. Epub 2013 Jan 3.

8.

Preventive chemotherapy in human helminthiasis: theoretical and operational aspects.

Gabrielli AF, Montresor A, Chitsulo L, Engels D, Savioli L.

Trans R Soc Trop Med Hyg. 2011 Dec;105(12):683-93. doi: 10.1016/j.trstmh.2011.08.013. Epub 2011 Oct 29.

9.

The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).

Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA.

PLoS Negl Trop Dis. 2010 Jun 1;4(6):e708. doi: 10.1371/journal.pntd.0000708.

10.

Mathematical models for lymphatic filariasis transmission and control: Challenges and prospects.

Swaminathan S, Subash PP, Rengachari R, Kaliannagounder K, Pradeep DK.

Parasit Vectors. 2008 Feb 12;1(1):2. doi: 10.1186/1756-3305-1-2.

11.

The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt.

El-Setouhy M, Abd Elaziz KM, Helmy H, Farid HA, Kamal HA, Ramzy RM, Shannon WD, Weil GJ.

Am J Trop Med Hyg. 2007 Dec;77(6):1069-73.

Supplemental Content

Support Center